Welcome to our dedicated page for Iridex SEC filings (Ticker: IRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Iridex Corporation (IRIX) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq Capital Market issuer incorporated in Delaware with principal offices in Mountain View, California, Iridex uses SEC reports to present information on its ophthalmic laser business, financial condition, and material events.
Key documents for IRIX include Form 10‑K annual reports, which describe the company’s business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for glaucoma, diabetic macular edema (DME), and other retinal diseases. Form 10‑Q quarterly reports provide interim updates on revenues from consoles, delivery devices, consumables, services, and support activities, along with segment information for its ophthalmology operations.
Iridex also files Form 8‑K current reports to announce specific events. Recent 8‑Ks have covered preliminary financial results, quarterly earnings releases, participation in investor conferences, and Nasdaq listing compliance matters, including the company’s notification of non‑compliance with Listing Rule 5550(b) and subsequent confirmation that it regained compliance with the stockholders’ equity requirement.
Investors can further review registration statements, proxy materials, and insider transaction reports such as Form 4, where applicable, to understand equity ownership and governance. On Stock Titan, AI-powered tools summarize lengthy filings, highlight key sections, and help explain complex topics such as non‑GAAP adjusted EBITDA reconciliations, stockholders’ equity, and risk factor disclosures, allowing users to navigate Iridex’s regulatory history more efficiently.
Iridex Corp Chief Financial Officer Romeo R. Dizon reported purchases of common stock on 08/26/2025. The filing shows two open-market buys: 750 shares at $1.26 and 250 shares at $1.25, for a total of 1,000 shares acquired. Following these transactions his beneficial ownership increased to 49,745 shares. The Form 4 was signed by an attorney-in-fact on 08/27/2025 and contains no derivative transactions or additional explanatory notes.
Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported four separate purchases of common stock on 08/25/2025. Each transaction (code P) was for 250 shares at prices of $1.25, $1.245, $1.24 and $1.2454, increasing his reported beneficial ownership sequentially to 47,995, 48,245, 48,495 and 48,745 shares. The Form 4 was signed by an attorney-in-fact on 08/26/2025.
Insider purchases increased stake in IRIDEX Corp. Romeo R. Dizon, the company's Chief Financial Officer, acquired a total of 1,000 shares of IRIDEX common stock on 08/22/2025 in three open-market transactions priced at $1.21, $1.22 and $1.23 per share. Following these purchases his reported beneficial ownership rose from 46,995 to 47,745 shares. The Form 4 was signed by an attorney-in-fact on 08/25/2025.
Iridex Corp (IRIX) Form 4: Chief Financial Officer Romeo Dizon reported two purchases on 08/21/2025 totaling 2,000 shares of common stock. The first purchase was 1,000 shares at $1.27 and the second was 1,000 shares at $1.22. Beneficial ownership increased to 46,745 shares following the transactions. The form was signed 08/22/2025 by an attorney-in-fact.
Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported two open-market purchases on 08/20/2025. He acquired 825 shares at $1.17 and 175 shares at $1.25, bringing his reported beneficial ownership to 44,745 shares following the transactions. The Form 4 was signed by an attorney-in-fact on 08/21/2025.
The filing lists Mr. Dizon's address in Mountain View, CA, and indicates the report was filed by one reporting person. No derivative transactions or additional explanations were provided in the filing.
Iridex Corp (IRIX) reported insider purchases by Chief Financial Officer Romeo R. Dizon on 08/19/2025. The reporting person acquired a total of 1,500 shares through three purchase transactions: 1,000 shares at $1.18, 500 shares at $1.16, and an aggregate line showing 1,500 shares at $1.1593, bringing his direct holdings to 43,745 shares after the trades. The Form 4 was signed by an attorney-in-fact on 08/20/2025.
William M. Moore, a director of Iridex Corporation (IRIX), reported purchases of the company’s common stock on 08/18/2025. The filing shows he acquired 12,024 shares at a weighted average price of $1.1834 per share (prices ranged from $1.175 to $1.1899). After the purchases, Mr. Moore directly beneficially owned 200,674 shares. The filing also discloses indirect holdings of 69,300 shares held by his spouse and 30,026 shares held in two trusts where he and his spouse serve as trustees/tenants in common. The Form 4 was signed on behalf of Mr. Moore by an attorney-in-fact on 08/19/2025.
Iridex Corp (IRIX) insider purchase reported. Romeo R. Dizon, listed as Chief Financial Officer and reporting person, acquired a total of 1,500 shares on 08/18/2025 in two transactions: 460 shares at $1.19 and 1,040 shares at $1.1723. After these purchases he is shown as beneficially owning 40,745 shares.
Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported two open-market purchases of company common stock on 08/15/2025. He acquired 1,000 shares at $1.1799 per share and 500 shares at $1.15 per share, bringing his total reported beneficial ownership to 39,245 shares following the transactions. The Form 4 was signed on behalf of Mr. Dizon by an attorney-in-fact on 08/18/2025. No derivative transactions or other material changes were reported in this filing.
IRIDEX Corporation reported quarterly revenue of $13.6 million (up 7.4% year-over-year) and six-month revenue of $25.5 million (up 4.4%). Gross margin for the quarter was 34.5% versus 40.7% a year earlier, and six-month gross margin was 38.2%. The company recorded a net loss of $0.99 million for the quarter and $2.68 million for the six-month period. Cash and cash equivalents rose to $6.8 million and working capital was $13.2 million, supported by financing activity.
The company completed financings including issuance of 600,000 Series B preferred shares for $6.0 million and a $4.0 million convertible note; it also recognized a $1.3 million loss on extinguishment of a prior convertible note. Topcon remains a material related-party customer, representing ~32% of quarterly revenue and ~29% of accounts receivable. Inventories were $8.4 million and deferred revenue ended at $9.9 million.
FAQ
What is the current stock price of Iridex (IRIX)?
What is the market cap of Iridex (IRIX)?
